Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-2445
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pharmacogenomics in Early-Phase Clinical Development

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2013English

Predictors of Success of Phase II Pediatric Oncology Clinical Trials

Oncologist
Cancer ResearchMedicineOncology
2019English

A Comparison of Screening Methods in Two Early Phase Oral Leukoplakia Clinical Trials

Oral Diseases
OtorhinolaryngologyDentistry
2012English

Phase II Cancer Clinical Trials for Biomarker-Guided Treatments

Journal of Biopharmaceutical Statistics
StatisticsProbabilityPharmacology
2017English

Borrowing Information Across Subgroups in Phase II Trials: Is It Useful?

Clinical Cancer Research
Cancer ResearchOncology
2013English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Critical Appraisal of Clinical Trials in Oncology — Part II

Oncology in Clinical Practice
Oncology
2019English

Screened Selection Design for Randomised Phase II Oncology Trials: An Example in Chronic Lymphocytic Leukaemia

Trials
MedicinePharmacology
2011English

Perceptions and Referral Trends Into Phase I Oncology Trials: Results of a Clinical Survey

Journal of Oncology
Oncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy